Are you currently taking anti-estrogen medication (tamoxifen, arimidex, etc.) to treat or prevent breast cancer, or have been or are on Hormone Replacement Therapy?
Our findings suggest that estrogen withdrawal can trigger cancer in women with the KRAS-variant.
Did you know that 1 in 5 women diagnosed with breast cancer have the KRAS-variant?
You may be eligible for one of several studies about the KRAS-variant, which seek to find the best ways to prevent the first and second cancers in individuals with the KRAS-variant.
What we know about the KRAS-variant:
- Cancer risk may be triggered by estrogen withdrawal
- Cancer risk may be increased by anti-estrogen medications
- Found in 6-10% of the population
- Predicts sensitivity and resistance to several standard-of-care cancer treatments/therapies
- Associated with advanced endometriosis and infertility
The KRAS-variant is one of the most frequently identified inherited genetic markers associated with cancer. The latest research indicates the KRAS-variant shows great potential to guide disease prevention and management across cancer types through its unique interactions with hormones and cancer therapies.
Hope Through Knowledge
If any of the following describe you, you are eligible for KRAS-variant testing and our studies and we hope you will take the eligibility survey.
- You are on anti-estrogen therapy and have or have not been diagnosed with a second breast cancer
- You are or have been on hormone replacement therapy
- You have been diagnosed with any cancer
- Your family members have been diagnosed with breast, ovarian or lung cancer
TAKE THE ELIGIBILITY SURVEY
We encourage you to see if you are eligible to join a MiraKind study to help us discover meaningful ways to better treat patients with genetic mutations. If you would like to join a study, please click the button below. You will be able to choose to get your KRAS-variant results at a discounted cost ($195) through the study. If you would prefer to directly order KRAS-variant testing at cost ($295) without joining a study, please follow this link.
MiraKind’s current research studies are designed to help answer the most pressing questions about the KRAS-variant and women’s cancer risk.
Current research questions include:
- Does hormone replacement therapy protect women with the KRAS-variant from developing cancer?
- How does anti-estrogen medication used to prevent reoccurrence of a first breast cancer, impact the risk of a second breast cancer for women with the KRAS-variant?